Page 3 - Cadila Healthcare

Stocks to watch: RCFL, Tata Motors, RIL, BEML, Cadila Health, Adani Green

Tata Motors reported a 21 per cent increase in total vehicle sales in the domestic market to 53,430 units in December

Cadila Healthcare completes phase-2 trial of Hepatitis C drug for Covid-19

95% subjects in the test who received a single dose of PegiHepTM along with SOC became virus free as assessed by RT-PCR on day 14, compared to 68% of those who only received SOC

Indices rally for 5th straight day, Sensex up 553 pts; RIL, financials gain

All that happened in the markets today

Cadila Healthcare rallies 9% on strong September quarter results

In Q2FY21, Cadila's Ebitda margins improved by 370 basis points at 22.6% against 18.9% in Q2FY20.

Govt to prioritise Covid-19 vaccine for front line health workers: Report

The national vaccine distribution plan is being formulated with the assumption that limited volumes of the inoculation will be available in the first few months of production, Paul said

Cadila scouts partners to ramp up Covid vaccine production by 50 to 70 mn

The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its plasmid DNA vaccine

Cadila: Rebound in domestic formulations to add to US sales, drive earnings

In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages

Cadila Healthcare rises 4% on launch of pressurized Metered Dose Inhaler

Forglyn pMDI is priced at Rs 495 per pack and has been developed in-house using Zydus' innovations in formulation technology

Covid-19 prescription: Pharma players shift their focus over the counter

The pandemic pushes pharma companies to look at drugs that held promise in transitioning to over the counter segment

Covid-19: At Rs 2,800 per dose, Zydus launches cheapest remdesivir brand

Zydus plans to supply large quantities of the injectable drug in the market soon

Zydus launches cheapest remdesivir at Rs 2,800 per 100 mg vial in India

Potential Covid-19 treatment drug launched under brand name Remdac in India

US-led growth helps Cadila post steady Q1 show even as India biz falters

While India business disappointed, lower expenses helped margins

Cadila Healthcare slips 4.5% from day's high post June quarter results

The stock of the pharmaceutical firm declined 4.5 per cent from its intra-day high of Rs 411.60, also its 52-week high, touched earlier in the day.

Nifty view and stock picks by Anand Rathi: Buy Tata Consumer, Sell Escorts

The stock of Tata Consumer Products made a fresh all-time high and has provided breakout from a cup pattern on the daily chart

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Here's a Bull Spread strategy for Cadila Healthcare by HDFC Securities

Long build up is seen in the Cadila Futures' where we have seen 6%(Prov) rise in the Open Interest with price moving up by 2%

Cadila gains 5% on DGCI nod for clinical trials of Covid-19 vaccine

The company has completed preclinical development and plans to begin the trials in July 2020

Cadila's renewed focus on India biz, Covid-19 opportunities lend confidence

Renewed focus on India, new drug launches in US lend comfort

Cadila-CSIR's sepsis drug shows promise in fight against Covid-19

The public-private partnership trial-generated data will be soon presented before the country's drug regulator to see if it can get emergency-use authorisation.

Cadila Healthcare's Q4 PBT falls 14% to Rs 522 cr, total income rises 0.66%

Cadila has also been working on a DNA vaccine to fight Covid-19, which is currently in the animal testing stage